News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Array BioPharma, Inc. (ARRY) Exec Settles Insider Trading Suit


8/22/2012 7:10:08 AM

The Securities and Exchange Commission has settled allegations of insider-trading against a former manager of Boulder-based Array BioPharma Inc., the Daily Camera reports.

The SEC alleged James L. Lieberman traded shares of the company's stock based on his knowledge of an impending drug-development agreement with Novartis Inc. Lieberman, who was Array BioPharma's manager of environmental health and safety from 2001 to 2010, has paid a $147,628 to end the case. He hasn't admitted or denied the SEC's allegations.

The penalty against Lieberman amounts to the $71,361 in profits he made from the stock sale, the same amount as a one-time civil penalty, and prejudgment interest of $4,906.


Read at Denver Business Journal
Read at SF Gate
Read at News Release
Read at News Release
Read at Pharmalot

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES